RNAZ
Transcode Therapeutics, Inc.
$5.33
-6.33%
$5.1M
No data for this timeframe.
Vol
Market Cap$5.1M
Cap SizeNano Cap
Inst. Holders4 funds
Inst. Value$82.5K
Reddit Sentiment60° Warm
SEC Reports5
Recent Activity
Jun 3, 2026
SEC
TransCode Therapeutics announced successful completion of its Phase 1a dose escalation trial for TTX-MC138 in metastatic
8-K — Impact 6/10
May 26, 2026
SEC
Transcode Therapeutics received a Nasdaq deficiency notice for failing to meet the $2.5M minimum stockholders' equity re
DEFA14A — Impact 6/10
Apr 30, 2026
SEC
TransCode Therapeutics filed an S-3 registration statement to register up to 15,955,543 shares of common stock for resal
S-3 — Impact 8/10
Feb 6, 2026
short_interest
FTD: RNAZ — 86,370 shares ($0.9M) failed to deliver
Settlement: 20260206, Price: $9.97, FTD Value: $861,108.9, TRANSCODE THERAPEUTICS INC COM
Analyst Ratings
2Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 16, 2025 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Mar 13, 2025 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Feb 7, 2025 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Feb 6, 2025 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Dec 18, 2024 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
Latest Reports
BULLISH
8-K
6/10
TransCode Therapeutics announced successful completion of its Phase 1a dose escalation trial for TTX-MC138 in metastatic
Jun 3, 2026
BEARISH
DEFA14A
6/10
Transcode Therapeutics received a Nasdaq deficiency notice for failing to meet the $2.5M minimum stockholders' equity re
May 26, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| ROYAL BANK OF CANADA | — | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $56.4K | — |
| VANGUARD FIDUCIARY TRUST CO | $25.7K | — |
| WELLS FARGO & COMPANY/MN | $474.00 | — |
Reddit Sentiment
60°
Warm
Bearish
Neutral
Bullish
4 institutional holders with $82.5K total value (9,590 shares) as of 2026-Q1. Top holders: ROYAL, VANGUARD, VANGUARD.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | ROYAL BANK OF CANADA | 8 | $0.00 | 0.0% | — |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 6,545 | $56.4K | 68.3% | — |
| 3 | VANGUARD FIDUCIARY TRUST CO | 2,982 | $25.7K | 31.1% | — |
| 4 | WELLS FARGO & COMPANY/MN | 55 | $474.00 | 0.6% | — |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
5 SEC filing reports analyzed. Sentiment: 1 bullish, 3 bearish, 1 mixed, 0 neutral. Avg impact: 6.6/10.
BULLISH
8-K
6/10
TransCode Therapeutics announced successful completion of its Phase 1a dose escalation trial for TTX
Jun 3, 2026
BEARISH
DEFA14A
6/10
Transcode Therapeutics received a Nasdaq deficiency notice for failing to meet the $2.5M minimum sto
May 26, 2026
BEARISH
S-3
8/10
TransCode Therapeutics filed an S-3 registration statement to register up to 15,955,543 shares of co
Apr 30, 2026
BEARISH
8-K
7/10
Transcode Therapeutics secured up to $20 million in flexible financing through a $6 million converti
Apr 7, 2026
MIXED
DEFA14A
6/10
TransCode Therapeutics filed a proxy statement (DEFA14A) related to a shareholder vote on the issuan
Mar 3, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Apr 2025): 86% buy across 7 analysts — 2 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2025-03-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2025-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 16, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 13, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Feb 7, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Feb 6, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Dec 18, 2024 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Nov 15, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Oct 24, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Sep 6, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Aug 15, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 29, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 16, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 16, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 3, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2025 | 2 | 4 | 1 | 0 | 0 | 86% | |
| May 1, 2025 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Apr 1, 2025 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2025 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
60°
Warm
Bearish
Neutral
Bullish
1 mentions
1 bullish
0 bearish
1 time period
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Feb 5, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
RNAZ w/news catalyst
▲ 1
💬 0
⚡ 0.0
Feb 6, 2026
short_interest
FTD: RNAZ — 86,370 shares ($0.9M) failed to deliver
Settlement: 20260206, Price: $9.97, FTD Value: $861,108.9, TRANSCODE THERAPEUTICS INC COM